Log In Sign up
The largest database of trusted experimental protocols

V cholerae neuraminidase

Manufactured by Roche
Visit Supplier
Sourced in United States

V. cholerae neuraminidase is a laboratory tool used to cleave sialic acid residues from glycoconjugates. It is an enzyme derived from the bacterium Vibrio cholerae. The core function of this product is to facilitate the removal of sialic acid groups from various biomolecules, which can be useful in certain research and analytical applications.

Automatically generated - may contain errors

Lab products found in correlation

Penicillin, by Thermo Fisher Scientific (2 mentions) Streptomycin, by Thermo Fisher Scientific (2 mentions) L glutamine, by Thermo Fisher Scientific (2 mentions) Fetal bovine serum (fbs), by GE Healthcare (2 mentions) Camp elisa kit, by R&D Systems (1 mentions) T84 cells, by American Type Culture Collection (1 mentions)

3 protocols using v cholerae neuraminidase

1

Colorectal Carcinoma Cell Culture

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
T84 cells (American Type Culture Collection—CCL-248), a line derived from a lung metastasis of a human colorectal carcinoma, were used as previously described [55 (link)]. The active (AB5) form of Ctx, 4 kDa labeled FITC-dextran and 1,2-diamino-4,5-methylenedioxybenzene (DMB) were obtained from Sigma-Aldrich (St. Louis, MO, USA). V. cholerae neuraminidase was purchased from Roche (Clovis, CA, USA). The cAMP ELISA kit was from R&D Systems (Minneapolis, MN, USA). V. cholerae strain N16961 was acquired from ATCC (Manassas, VA, USA).
Alisson-Silva F., Liu J.Z., Diaz S.L., Deng L., Gareau M.G., Marchelletta R., Chen X., Nizet V., Varki N., Barrett K.E, & Varki A. (2018). Human evolutionary loss of epithelial Neu5Gc expression and species-specific susceptibility to cholera. PLoS Pathogens, 14(6), e1007133.
+ Open protocol
+ Expand
2

Neuraminidase Treatment of Tumor Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Single-cell suspensions of human tumor digests were prepared as described above, thawed, and seeded in RPMI 1640 medium supplemented with 10% heat-inactivated FBS (PAA Laboratories), 2 mM l-glutamine, 1 mM sodium pyruvate, streptomycin (100 μg/ml), and penicillin (100 U/ml) (all Gibco). The cells were then treated with V. cholerae neuraminidase (10 mU/ml; Roche) for 48 hours. Supernatants were frozen at −80°C, and the cells were stained for markers of T cell activation.
Stanczak M.A., Mantuano N.R., Kirchhammer N., Sanin D.E., Jacob F., Coelho R., Everest-Dass A.V., Wang J., Trefny M.P., Monaco G., Bärenwaldt A., Gray M.A., Petrone A., Kashyap A.S., Glatz K., Kasenda B., Normington K., Broderick J., Peng L., Pearce O.M., Pearce E.L., Bertozzi C.R., Zippelius A, & Läubli H. (2022). Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Science translational medicine, 14(669), eabj1270.
+ Open protocol
+ Expand
3

Neuraminidase Treatment of Tumor Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Single-cell suspensions of human tumor digests were prepared as described above, thawed, and seeded in RPMI 1640 medium supplemented with 10% heat-inactivated FBS (PAA Laboratories), 2 mM l-glutamine, 1 mM sodium pyruvate, streptomycin (100 μg/ml), and penicillin (100 U/ml) (all Gibco). The cells were then treated with V. cholerae neuraminidase (10 mU/ml; Roche) for 48 hours. Supernatants were frozen at −80°C, and the cells were stained for markers of T cell activation.
Stanczak M.A., Mantuano N.R., Kirchhammer N., Sanin D.E., Jacob F., Coelho R., Everest-Dass A.V., Wang J., Trefny M.P., Monaco G., Bärenwaldt A., Gray M.A., Petrone A., Kashyap A.S., Glatz K., Kasenda B., Normington K., Broderick J., Peng L., Pearce O.M., Pearce E.L., Bertozzi C.R., Zippelius A, & Läubli H. (2022). Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Science translational medicine, 14(669), eabj1270.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!